The effect of IL28B haplotype on hepatitis C virus infection and treatment response

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1006759

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

About 3% of the world population is currently infected with hepatitis C virus (HCV). Most have chronic infection with a high risk for progressive liver fibrosis and subsequent liver cirrhosis and hepatocellular carcinoma. We have recently demonstrated genetic variants of the IL28B gene predict viral clearance with and without treatment after HCV infection. Determining why will impact on the development of new therapies, optimise use of current therapies, and identify patients who may respond to alternative therapies.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: NHMRC Project Grants

Funding Amount: $525,576.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Gastroenterology and Hepatology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

drug efficacy | genetics | hepatitis C infection | hepatology | interferon (IFN) | liver disease

Related Links